Thena Capital, a London-based venture firm, has successfully closed its first fund at £45 million ($60.4 million), marking a significant milestone in the UK’s medical technology investment landscape. The firm, which was initially announced with a £27 million first close in March 2025, has now reached full commitment, signaling strong confidence in its strategy and team. This achievement is especially notable as Thena Capital is the first venture firm in the UK to be led entirely by an all-female general partner team.
Focus on Early-Stage Medtech Innovation
The newly closed fund will specifically target early-stage medical technology companies based in the UK. These investments are aimed at supporting the development of innovative solutions that address critical healthcare challenges. By focusing on emerging medtech firms, Thena Capital is positioning itself at the forefront of a rapidly growing sector, where advancements in AI, digital health, and precision medicine are reshaping the industry.
Breaking Barriers in Venture Capital
The significance of Thena Capital’s all-female general partner team cannot be understated. Despite the increasing presence of women in the tech and investment sectors, leadership roles in venture capital remain predominantly male. The firm’s success not only highlights the importance of diversity in investment decision-making but also challenges traditional norms in the industry. With a clear vision and strategic approach, the team is proving that gender diversity can drive both financial returns and social impact.
Looking Ahead
As Thena Capital moves forward, its £45 million fund will likely attract attention from other investors and entrepreneurs. The firm’s ability to secure significant capital while maintaining a unique team composition sets a new precedent in the UK’s venture capital ecosystem. With continued support from government and private investors, Thena Capital is poised to play a crucial role in nurturing the next generation of British medtech innovators.
